Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 7, Issue 2 , Pages 151-160, March 2011

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

Pfizer Global Research and Development, New London, CT, USA

published online 02 September 2010.

Abstract 

Background

A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Initiative.

Methods

The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein ɛ4 [APOE ɛ4] genotype, gender, family history of AD, years of education) and baseline severity were tested as covariates.

Results

Rate of disease progression increased with baseline severity. Age, APOE ɛ4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr.

Conclusions

A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE ɛ4 genotype, and gender also influence the rate of disease progression.

Keywords: Disease progression model, Natural history, ADAS-cog, MCI, Alzheimer's disease, Age, APOE ɛ4 genotype

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Alzheimer's Disease Neuroimaging Initiative: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at www.loni.ucla.edu\ADNI\Collaboration\ADNI_Authorship_list.pdf).

PII: S1552-5260(10)00103-2

doi:10.1016/j.jalz.2010.03.018

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 7, Issue 2 , Pages 151-160, March 2011